Sanofi Pasteur, Institut Pasteur Team Up Against Malaria
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced a partnership with Institut Pasteur to develop a vaccine against malaria. Under this collaboration agreement, Sanofi Pasteur will have access to antigens identified by Institut Pasteur derived from Plasmodium falciparum, the parasite responsible for the most deadly malaria infections. Sanofi Pasteur intends to use these antigens with the goal of developing a safe and efficacious candidate vaccine against malaria.
"Sanofi Pasteur is committed to making malaria a vaccine-preventable disease, ultimately relieving affected populations from this scourge," said Wayne Pisano, President and Chief Executive Officer of Sanofi Pasteur. "Sanofi Pasteur is continuously exploring new paths to develop innovative vaccines and this agreement with Institut Pasteur underlines the company's historical involvement in public-private partnerships with renowned institutions to help improve public health."
The World Health Organization estimates that approximately 40% of the world's population, mostly those living in the world's poorest countries, are at risk of malaria. Every year, more than 500 million people become severely ill with malaria. Of those, more than one million people die every year--mostly infants, young children and pregnant women--the majority of which are in Africa, specifically, sub-Saharan Africa.
"Institut Pasteur has discovered several promising antigens over the last decade that we believe could lead to malaria vaccines to protect children living in endemic regions as well as travellers," said Pr. Alice Dautry, President of Institut Pasteur. "Teaming with Sanofi Pasteur, a long-standing partner of the institute, increases the potential to reach the shared goal of a malaria vaccine. Through this agreement, Institut Pasteur and Sanofi Pasteur reinforce their collaboration to benefit public health."
Sanofi Pasteur's malaria vaccine project is currently in the preclinical phase and is expected to benefit from a network of partnerships.